Article

Periodontal and oral manifestations of marijuana use

Department of Periodontology, University of Tennessee Health Science Center, College of Dentistry, Memphis, TN, USA.
The Journal of the Tennessee Dental Association 11/2012; 92(2):26-31; quiz 31-2.
Source: PubMed

ABSTRACT

Marijuana, prepared from the plant Cannabis sativa, is the most widely used illicit drug in the United States. Marijuana use has been associated with adverse psychosocial and health effects, including effects on oral tissues. Periodontal literature has limited references to the periodontal effects of cannabis use. In this report, we present two cases of marijuana-associated gingival enlargement and review the literature on oral complications of marijuana use.
Two asymptomatic males, aged 23 and 42 years, presented independently for oral prophylaxis. Both had an unremarkable medical history and related a history of significant marijuana use of 2-16 years duration. Common findings following oral and periodontal examination were nicotinic stomatitis-like lesions, uvulitis and gingival enlargement. Marginal and papillary gingiva of the anterior dentition were the areas primarily affected by gingival enlargement, while some of these areas exhibited a nodular or "pebbly" appearance.
Marijuana-associated gingival enlargement was diagnosed in the reported cases. A review of the literature revealed two other reports of marijuana-associated gingival enlargement, all in young adult males with chronic (2 or more years) cannabis use. These authors reported a resemblance to phenytoin-induced enlargement. Biochemical similarities between phenytoin and cannabis active compounds suggest possible common pathogenetic mechanisms. Uvulitis and nicotinic stomatitis appear to be the two most common of the several oral manifestations of marijuana use.
Chronic marijuana use may result in gingival enlargement with clinical characteristics similar to phenytoin-induced enlargement.

Download full-text

Full-text

Available from: Dimitris N Tatakis
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: New designer drugs (synthetic cannabinoids and synthetic cathinones) are new "legal highs" that are sold online for recreational public or private use. Synthetic cannabinoids are psychoactive herbal and chemical products that mimic the effects of cannabis when used. These drugs are available on the Internet or in head shops as incense or air fresheners to circumvent the law. Cathinone is a naturally occurring beta-ketone amphetamine analog found in the leaves of the Catha edulis plant. Synthetic cathinones are phenylalkylamine derivatives that may possess amphetamine-like properties. These drugs are sold online as bath salts. Designer drugs are often labeled as "not for human consumption" to circumvent drug abuse legislation. The absence of legal risks, the ease of obtaining these drugs, the moderate cost, and the availability via the Internet are the main features that attract users, but the number of intoxicated people presenting with emergencies is increasing. There is evidence that negative health and social consequences may affect recreational and chronic users. The addictive potential of designer drugs is not negligible.
    Full-text · Article · Aug 2013 · Current pharmaceutical design
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cannabis remains the most commonly used and trafficked illicit drug in the world. Its use is largely concentrated among young people (15- to 34-year-olds). There is a variety of cannabis use patterns, ranging from experimental use to dependent use. Men are more likely than women to report both early initiation and frequent use of cannabis. Due to the high prevalence of cannabis use, the impact of cannabis on public health may be significant. A range of acute and chronic health problems associated with cannabis use has been identified. Cannabis can frequently have negative effects in its users, which may be amplified by certain demographic and/or psychosocial factors. Acute adverse effects include hyperemesis syndrome, impaired coordination and performance, anxiety, suicidal ideations/tendencies, and psychotic symptoms. Acute cannabis consumption is also associated with an increased risk of motor vehicle crashes, especially fatal collisions. Evidence indicates that frequent and prolonged use of cannabis can be detrimental to both mental and physical health. Chronic effects of cannabis use include mood disorders, exacerbation of psychotic disorders in vulnerable people, cannabis use disorders, withdrawal syndrome, neurocognitive impairments, cardiovascular and respiratory and other diseases.
    Full-text · Article · Aug 2013 · Current pharmaceutical design
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ZUSAMMENFASSUNG Hintergrund: Cannabis ist die am häufigsten konsumierte illegale Droge welt-weit. In Deutschland wird sie jährlich von circa 4,5 % aller Erwachsenen ver-wendet. Ein intensiver Cannabiskonsum ist mit gesundheitlichen Risiken assozi-iert. Zur Behandlung von gesundheitlichen Störungen infolge von Cannabisge-brauch stehen evidenzbasierte Interventionsmöglichkeiten zur Verfügung. Methode: Es erfolgte eine selektive Literaturrecherche in PubMed mit besonde-rem Schwerpunkt auf systematischen Reviews, Metaanalysen, Kohortenstudien, randomisiert-kontrollierten Studien (RCTs), Fallkontrollstudien und Behandlungs-leitlinien. Ergebnisse: Der Gehalt von Delta-9-Tetrahydrocannabinol in Cannabisprodukten steigt durch Züchtung weltweit an, wohingegen Cannabidiol häufig nicht mehr nachweisbar ist. Abhängig von Alter, Dosis, Frequenz, Applikationsform, Situation und individueller Disposition eines Menschen können unterschiedliche akute Folgeschäden durch Cannabiskonsum auftreten. Hierzu gehören Panikattacken, psychotische Symptome, beeinträchtigte Aufmerksamkeit, mangelnde Konzen-tration, gestörte motorische Koordination und Übelkeit. Insbesondere ein hoch-dosierter, langjähriger und intensiver Cannabisgebrauch sowie ein Konsumbe-ginn im Jugendalter kann mit einer Abhängigkeit (DSM-5; ICD-10), spezifischen Entzugssymptomen, kognitiven Einbußen, affektiven Störungen, Psychosen, Angststörungen und körperlichen Schädigungen (vor allem respiratorische und kardiovaskuläre Erkrankungen) einhergehen. Eine Kombination aus Motivations-förderung, kognitiver Verhaltenstherapie und Kontingenzmanagement sind aktu-ell die effektivsten Behandlungsansätze der Cannabisabhängigkeit (Evidenzgrad: 1a). Für Jugendliche werden ebenfalls familientherapeutische Interventionen empfohlen (Evidenzgrad: 1a). Aufgrund geringer Evidenz können bisher keine pharmakologischen Behandlungsempfehlungen gegeben werden. Schlussfolgerungen: Weitere Forschung ist notwendig, um die Kausalität des Zu-sammenhangs von intensivem Cannabiskonsum und möglichen Folgen für die körperliche und psychische Gesundheit zu klären. Gesundheitliche Störungen in-folge von Cannabiskonsum können effektiv behandelt werden. ►Zitierweise Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW: Risks associated with the non-medicinal use of cannabis.
    Full-text · Article · Apr 2015
Show more